Abstract
Evidence for the efficacy and safety of intravesical onabotulinum toxin A (onabotA) injections has led to it being licensed in many countries in patients with urinary incontinence due to neurogenic detrusor overactivity resulting from spinal cord injury and multiple sclerosis, who are refractory or intolerant to the gold-standard treatment, anticholinergics. Owing to its mechanism of action, an inhibitory effect on acetylcholine release is obtained for up to 10 months, with a recommended dose of 200 units. Urinary tract infections and postvoid residual volume are the most prevalent side effects. In the case of residual volume, clean intermittent catheterization might be necessary. In patients with spinal cord injury and multiple sclerosis, it is recommended to evaluate the manual dexterity and cognitive function before onabotA injections, to ensure that the patient and caregiver are able to perform catheterization if necessary. OnabotA treatment has a beneficial effect not only on urinary symptoms but also on quality of life.
Financial & competing interests disclosure
KC Everaert is an investigator for Allergan and receives consultancy and speaker fees. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.